Evotec (EVT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Jun, 2026Executive summary
Annual Meeting scheduled for August 6, 2026, at the principal office in Boston, MA, for five Eaton Vance funds.
Main agenda is the election of Class II Trustees for each fund, with voting by shareholders of record as of June 2, 2026.
Proxy materials, including the proxy statement and shareholder reports, are available online and by request.
Shareholders are encouraged to vote by proxy even if not attending in person; proxies are revocable.
Voting matters and shareholder proposals
Election of Trustees is the sole proposal, with specific nominees for each fund and share class.
Shareholders may also act on any other matters properly brought before the meeting.
Shareholder proposals for the 2027 meeting must be submitted by February 23, 2027, for inclusion.
Board of directors and corporate governance
Each fund's board consists of nine noninterested Trustees, divided into three classes with staggered three-year terms.
Trustees have diverse backgrounds in investment management, academia, and corporate governance.
Board committees include Audit, Contract Review, Governance, Portfolio Management, Compliance, and Closed-End Fund Committees.
Board and committee meetings are held regularly, with all Trustees attending at least 75% of meetings in 2025.
Governance Committee considers diversity and overall board composition in nominating Trustees.
Latest events from Evotec
- Operational excellence, pipeline growth, and asset-light strategy drive sustainable value creation.EVT
Company presentation17 Jun 2026 - Q1 2026 revenues fell to €156.6m as transformation and cost-saving measures advanced.EVT
Q1 20266 May 2026 - Strong biologics growth, cost efficiency, and asset monetization drive sustainable value creation.EVT
Company presentation24 Apr 2026 - Biologics growth and cost discipline drive high-end 2025 results; Horizon targets €75m savings.EVT
Q4 20258 Apr 2026 - Transformation targets €75M savings by 2027 and >€1B revenues with 20%+ EBITDA margin by 2028.EVT
Status update10 Mar 2026 - Strong JEB growth, asset-light pivot, and robust pipeline drive mid-term value creation.EVT
Company presentation10 Mar 2026 - Revenue up 2%, but losses deepen and restructuring accelerates for 2025 recovery.EVT
Q2 20241 Feb 2026 - Biologics growth and cost savings offset R&D softness, supporting 2024 guidance.EVT
Q3 202416 Jan 2026 - Strong Q4, cost savings, and biologics growth set up 5–10% revenue rise in 2025.EVT
Q4 20242 Dec 2025